Brought to you by 
Follow-on offering nets $81.6mm for Orexigen
21 Aug 2009
Executive Summary
Obesity-focused Orexigen Therapeutics netted $81.6mm through a follow-on public offering of 10mm common shares (including the overallotment) at $7.50. The company plans to use part of the proceeds to prepare the NDA for its lead Contrave, and for ongoing Phase II trials of Empatic. Both candidates are under development for weight loss.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com